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New therapies for advanced, recurrent, and
metastatic endometrial cancers
Vicky Makker1*, Angela K. Green1, Robert M. Wenham2, David Mutch3, Brittany Davidson4 and David Scott Miller5
Abstract
Endometrial cancer is the most common gynecologic malignancy in the United States, accounting for 6% of cancers in
women. In 2017, an estimated 61,380 women were diagnosed with endometrial cancer, and approximately 11,000 died
from this disease. From 1987 to 2008, there was a 50% increase in the incidence of endometrial cancer, with an
approximate 300% increase in the number of associated deaths. Although there are many chemotherapeutic and
targeted therapy agents approved for ovarian, fallopian tube and primary peritoneal cancers, since the 1971 approval
of megestrol acetate for the palliative treatment of advanced endometrial cancer, only pembrolizumab has been Food
and Drug Administration (FDA)-approved for high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR)
endometrial cancer; this highlights the need for new therapies to treat advanced, recurrent, metastatic endometrial
cancer. In this review, we discuss current and emerging treatment options for endometrial cancer, including chemotherapy,
targeted therapy, and immunotherapy. The National Cancer Institute (NCI) and others are now focusing their efforts on the
design of scientifically rational targeted therapy and immunotherapy trials for specific molecular phenotypes of endometrial
cancer. This is essential for the advancement of cancer care for women, which is threatened by a severe enrollment decline
of approximately 80% for gynecologic oncology clinical trials.
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Introduction
Endometrial cancer (EC) is the most common gynecologic
malignancy in the United States, with an estimated 61,380
new cases and 11,000 deaths in 2017 [1]. The incidence of
EC is increasing annually by an estimated 1–2%. The
number of deaths attributed to EC are also increasing,
while the mortality rate for ovarian cancer is declining [2,
3]. Obesity is a strong risk factor for the development of
EC, accounting for approximately 50% of cases in Europe
and the United States; it also has been associated with a
relative increased risk of death of up to 6.25 [4].
Reduced birth rates, improvements in health and nutri-
tion, and changes in the social structure of developed
countries have led to an increasing elderly population, at a
rate of 2.4% per year [5]. With the aging population, health
promotion and disease prevention initiatives are warranted
for individuals older than 50 years of age [6]. Of note, most
EC diagnoses are made in women aged 45 to 74 years [3].
From 1987 to 2008, there was a 50% increase in the in-
cidence of EC, with an approximate 300% increase in
the number of associated deaths; however, no new
agents were approved for treating EC. Although there
are many drugs approved for the treatment of ovarian,
fallopian tube, and primary peritoneal cancers, to date,
there are only two FDA-approved drugs for EC,
highlighting the need for new therapies to treat ad-
vanced, recurrent, metastatic EC [7].
Review
Types of endometrial cancer
Endometrial adenocarcinomas can be classified into two
histologic categories—type 1 or type 2 [8]. Approxi-
mately 70–80% of new cases are classified as type 1
endometrial carcinomas, which are of endometrioid
histology, lower grade, and often confined to the uterus
at diagnosis. These tumors are estrogen-mediated, and
often, women diagnosed with type 1 endometrial carcin-
omas are obese, with excess endogenous estrogen pro-
duction. Type 1 carcinomas (estrogen dependent) have
high rates of K-ras and PTEN loss or mutation, as well
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as defects in mismatch repair genes, which lead to
microsatellite instability (MSI) [9–13]. Type 2 (non-es-
trogen dependent) carcinomas are higher-grade adeno-
carcinomas and are of non-endometrioid histology,
occurring in older, leaner women, although an associ-
ation with increasing body mass index (BMI) has been
observed. Type 2 cancers have p53 mutations, may have
overexpression of human epidermal growth factor recep-
tor 2 (HER-2/neu), and show aneuploidy [14–20]. It
should be noted that there are limitations to this dualis-
tic classification of ECs, as there is heterogeneity and
often overlap of the underlying genetics; for example,
many high-grade endometrioid cancers can harbor p53
mutations and behave like other type 2 cancers. A recent
Gynecologic Oncology Group (GOG) study evaluated
the etiologic heterogeneity of ECs and reported that
women with type 2 cancers, compared with type 1 can-
cers, were less likely to be obese but more likely to be
older, non-white, multiparous, and current smokers [21].
Women with grade 3 endometrioid carcinomas dis-
played characteristics that were similar to those of type
2 cancers, but more often had histories of breast cancer
without tamoxifen exposure.
Uterine carcinosarcomas, a poorly differentiated sub-
group of uterine carcinomas, account for less than 5% of
all uterine malignancies and are rare, aggressive biphasic
neoplasms that consist of high-grade malignant epithelial
and mesenchymal elements [22]. Five-year progression-
free survival (PFS) rates for uterine-confined disease range
from 40 to 75%, compared with 20–35% for disease with
extra-uterine extension [23, 24].
The Cancer Genome Atlas (TCGA) Research Network
has performed the most comprehensive molecular study
of EC, integrating genomic, transcriptomic, and prote-
omic characterizations of EC based on array and sequen-
cing technologies in 373 primary EC surgical specimens
[25]. These data revealed that EC can be classified into
four molecularly phenotypically different groups: 1)
DNA polymerase epsilon catalytic subunit (POLE) ultra-
mutated (very high mutation rate, hot spot mutations in
POLE, endometrioid histology, frequently grade 3
[>50%], associated with a good prognosis, comprises 1%
of cases of recurrent disease, and characterized by muta-
tions in PTEN [94%], PIK3CA [71%], PIK3R1 [65%],
FBXW7 [82%], ARID1A [76%], KRAS [53%], and
ARID5B [47%]); 2) MSI hypermutated (high mutation
rate, microsatellite unstable, frequently with MLH-1 pro-
moter hypermethylation, endometrioid histology, com-
prises approximately 25% of cases of recurrent disease,
and characterized by mutations in PTEN [88%], RPL22
[33%], KRAS [35%], PIK3CA [54%], PIK3R1 [40%], and
ARID1A [37%]); 3) copy-number low (lower mutation
rate, microsatellite stable (MSS), endometrioid histology,
grade 1/2 tumors, and characterized by mutations in
PTEN [77%], CTNNB1 [52%], PIK3CA [53%], PIK3R1
[33%], and ARID1A [42%]); and 4) copy-number high
serous-like (lowest mutation rate, serous, comprises ap-
proximately 25% of grade 3 endometrioid cases, poorest
prognosis, and characterized by mutations in TP53
[92%], PPP2R1A [22%], PIK3CA [47%], and chromo-
somal instability).
The classification of EC by morphologic features is
irreproducible and imperfectly reflects tumor biology.
A molecular classification system based on the TCGA
genomic subgroups, referred to as the Proactive
Molecular Risk Classifier for Endometrial Cancer
(ProMisE), was developed to confirm the feasibility and
prognostic ability in a separate cohort of ECs [26].
ProMisE successfully categorized all cases and im-
proved subgroup discrimination compared with the
European Society of Medical Oncology (ESMO) risk
classification system.
A TCGA analysis of 57 primary uterine carcinosar-
coma tumor samples revealed extensive copy-number
alterations and highly recurrent somatic mutations.
Similar to endometrioid and serous endometrial carcin-
omas, mutations in TP53 (91%), PIK3CA (35%),
PPP2R1A (28%), FBXW7 (28%), PTEN (19%), FBXW7,
and KRAS (12%) were identified. A strong epithelial-to-
mesenchymal transition (EMT) gene signature was
observed in a subset of analyzed cases; the range of
EMT scores was the largest among all tumors studied
thus far by TCGA. Multiple somatic mutations and
copy-number alterations in genes that are therapeutic
targets were identified; 62% of tumors had one or more
potentially clinically relevant mutations in the PI3K/
AKT/mTOR pathway, and approximately 23% of cases
had alterations in cell-cycle genes [27].
Risk factors
Risk factors for EC include endometrial hyperplasia, un-
opposed estrogen therapy, tamoxifen use, obesity, repro-
ductive factors (early menarche/late menopause, nulliparity,
or polycystic ovarian syndrome), family history/genetic
predisposition, and hyperinsulinemia [28–34]. Lynch
syndrome, an autosomal dominant inherited cancer suscep-
tibility syndrome, is caused by a germline mutation in
mismatch repair (MMR) genes (MLH1, MSH2, MSH6, and
PMS2) and accounts for 2–5% of endometrial carcinomas
[35–37]. Women with Lynch syndrome have an approxi-
mate 70% lifetime risk of developing EC [38, 39]. MMR is a
single-strand DNA repair mechanism critical to maintain-
ing genomic stability. MMR genes can be lost via mutation
or methylation, with MMR deficiency associated with up to
30% of all ECs [25].
Type I EC oncogenesis is primarily estrogen dependent,
having a positive correlation with high circulating estrogen
levels [40, 41]. Prolonged exposure to estrogens through
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early menarche, late menopause, or the use of hormone
replacement therapy are known risk factors [42]. Further-
more, sex hormone production from adipose tissue leads
to estrogen stimulation of the endometrial lining [43].
Emerging data identify hyperinsulinemia, hypergly-
cemia, and chronic inflammation as potentially modifiable
risk factors for the development and progression of mul-
tiple malignancies, including EC. Numerous etiologies
lead to the development of the metabolic syndrome; how-
ever, obesity is dominant and has rising prevalence [44].
Based on National Health and Nutrition Examination
Survey (NHANES) data, since 1960, the percentages of
adults classified as overweight, obese, or extremely obese
have continued to increase [45]. Obese women (BMI
>30 kg/m2), compared with normal-weight women, are
at an increased risk of developing EC, with each 5 kg/m2
increase in BMI conferring additional risk [46, 47]. A re-
cent meta-analysis reported that, compared with
normal-weight women, the risk of developing EC was
1.34 times higher in overweight women and 2.54 times
higher in obese women [48]. Outcomes for EC also are
affected by obesity. A retrospective study of patients
with EC managed with surgery demonstrated that obese
women had significantly more perioperative complica-
tions [49]. In obese women, death rates from EC are
much higher compared with death rates in obese
patients with other malignancies, suggesting the import-
ance of the angiogenic tumor microenvironment related
to adiposity [46–48]. Currently, there are a myriad of
studies evaluating the impact of calorie restriction and
exercise in promoting weight loss in obese patients with
EC (NCT02665962, NCT02665962), as well as the im-
pact of ketogenic diet in overweight or obese patients
with newly diagnosed EC (NCT03285152).
Signaling pathways in endometrial cancer
One of the hallmarks of cancer is metabolic “addiction”
to glucose, which is partially due to alterations in mito-
chondrial structure and function that result from gen-
etic, epigenetic, and enzymatic alterations within cancer
cells [50–53]. Current research suggests that this prefer-
ential metabolism of glucose through glycolysis may
arise as a selective advantage in the hypoxic conditions
experienced during early tumor development [54]. This
cellular reprogramming of glucose metabolism to fuel
tumor cell growth is largely thought to be driven by the
AKTphosphoinositide 3-kinase (PI3K)/mammalian tar-
get of rapamycin (mTOR) pathway, which is commonly
activated in endometrial carcinomas.
In fact, EC demonstrates the highest rate of PI3K path-
way alterations of all solid tumors. The PI3K pathway also
regulates cell growth, survival and motility, all key aspects
of cancer cell biology. There are three classes of PI3K en-
zymes, which are grouped according to structure and
function. Class IA PI3Ks are most associated with promot-
ing carcinogenesis. Pathway activation begins with
membrane-associated receptor tyrosine kinases (RTKs),
such as the insulin-like growth factor receptor (IGFR),
which has more than five-fold increased expression in
endometrial adenocarcinoma compared with normal
endometrium [55]. Upon stimulation of RTKs, PI3K phos-
phorylates the lipid phosphatidylinositol 4,5- biphosphate
(PIP2), creating phosphatidylinositol 3,4,5- triphosphate
(PIP3). PIP3 recruits protein kinase AKT to the mem-
brane, where it is phosphorylated and activated by mTOR
complex 2 (mTORC2) and 3-phosphoinositide-dependent
protein kinase 1 (PDK1). Among its targets, AKT phos-
phorylates and inhibits tuberous sclerosis complex 2
(TSC2) within the TSC complex, which indirectly inhibits
mTOR complex 1 (mTORC1). PI3K-AKT signaling
activates mTORC1 [56], a key regulator of metabolism
and biosynthetic processes, including activation of
hypoxia-inducible factor 1 (HIF1) and other transcription
factors. HIF1 stimulates glucose transporter expression on
the cell surface, thereby increasing cellular glucose influx,
and shifts metabolic pathways towards glycolysis through
inhibitory mitochondrial pyruvate dehydrogenase kinase
activation [49, 57].
Obesity, due to physical inactivity and excess caloric
intake, leads to high glucose, insulin, and insulin-like
growth factor 1 (IGF-1) levels. Increased signaling via
the insulin/IGF-1 pathway culminates in activation of
the mTOR pathway, resulting in increased cell prolifera-
tion and cancer development. Elevated glucose levels
reduce 5′ adenosine monophosphate-activated protein
kinase (AMPK) levels, which in turn increase mTOR
stimulation and cell proliferation. Components of the
mTOR pathway are often mutated, amplified, or
aberrantly expressed in ECs, further supporting the link
between obesity and this disease [49].
Metastatic disease
Most women with EC are diagnosed at an early stage.
The 5-year survival rate for those diagnosed with lo-
calized disease is 95%; however, women diagnosed
with advanced or recurrent disease have a poor prog-
nosis, with a 5-year survival rate of 17% [3, 58]. In a
study of four GOG trials evaluating the relationship
between histology and outcomes of women with ad-
vanced, recurrent EC, the median overall survival
(OS) was less than 12 months, with PFS ranging from
3 to 6 months based on histology [59]. Unfortunately,
most current chemotherapeutic options for advanced
EC are associated with significant toxicity and limited
efficacy, highlighting the need to continue with efforts
to exploit the molecular underpinnings and biology of
this disease for target-specific and immunotherapeutic
approaches.
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Novel approaches for treating endometrial cancer
Adjuvant chemotherapy
Based on the findings of several GOG trials, platinum
doublet chemotherapy remains the mainstay for first-line
systemic therapy in patients with advanced EC. A phase 3
study of cisplatin plus doxorubicin demonstrated
improved response rates and PFS (5.7 vs 3.8 months)
compared with doxorubicin alone, but the regimen was
not associated with increased OS (9.0 vs 9.2 months) [60].
Following this trial, the GOG-122 study accrued 396
patients with stage III or IV EC and a maximum of 2 cm
of postoperative residual disease and randomized them to
treatment with whole-abdominal irradiation or
doxorubicin-cisplatin chemotherapy [61]. With a median
74 months of follow-up, patients in the chemotherapy
arm, compared with those in the radiation arm, had a sig-
nificantly improved 5-year survival rate (55% vs. 42%, re-
spectively); however, the chemotherapy arm was also
associated with greater toxicity. This pivotal study led to a
paradigm shift in the management of advanced-stage EC.
To further improve efficacy, the GOG-177 study was
designed to compare doxorubicin, cisplatin, paclitaxel and
filgrastim support (TAP) with doxorubicin and cisplatin.
Findings from the study demonstrated a significantly im-
proved response rate (57% vs 34%, respectively), PFS (8.3
vs 5.3 months, respectively), and OS (15.3 vs 12.3 months,
respectively; p = 0.037) with the former regimen, albeit
with significantly higher patient-reported neurotoxicity
[62]. In an effort to develop a less toxic regimen, GOG-
209 was designed to compare carboplatin and paclitaxel
(CT) to the triplet TAP regimen. This study demonstrated
that CT was not inferior to TAP in terms of PFS
(14 months in both arms) and OS (32 vs 38 months, re-
spectively; HR 1.01) [63]. The toxicity profile for CT was
significantly more favorable, and this regimen serves as
the acceptable backbone for chemotherapy trials.
A myriad of ongoing studies using CT as the chemo-
therapy backbone include a phase 1 study of the selective
inhibitor of nuclear export selinexor in combination with
CT in patients with advanced ovarian or endometrial
cancers (NCT02269293), a phase 2 study of the androgen-
receptor inhibitor enzalutamide in combination with CT
in advanced endometrioid EC (NCT02684227), a random-
ized phase 2 trial of CT compared to CT plus bevacizu-
mab in advanced-stage or recurrent EC (NCT01770171),
a phase 2 study of pembrolizumab in combination with
CT in advanced EC (NCT02549209), and a randomized
phase 2/3 study of CT plus metformin (NSC#91485) ver-
sus CT plus placebo as initial therapy in advanced-stage
or recurrent EC (NCT02065687).
Chemotherapy for uterine carcinosarcomas
In the GOG-108 study, patients with advanced or recur-
rent carcinosarcoma treated with the combination of
ifosfamide and cisplatin exhibited increased response rates
and longer PFS compared with patients who received ifos-
famide alone; no significant difference in survival was
reported [64]. Results from a follow-up trial (GOG-161)
demonstrated an increased response rate (29 vs 45%), me-
dian PFS (3.6 vs 5.8 months), and OS (8.4 vs 13.5 months)
in patients receiving a 3-day regimen of ifosfamide plus
paclitaxel versus paclitaxel alone [65]. As with ixabepilone
for EC treatment, a nearly identical and modest response
rate (12%), median PFS 1.7 months), and OS (7.7 months)
were seen in 34 patients with uterine carcinosarcoma in
the GOG-130F study [66]. Furthermore, as with treatment
of other ECs, the use of CT in uterine carcinosarcoma is
an appropriate option based on apparent equivalent effi-
cacy and better tolerability [67].
A phase 2 trial using CT as the chemotherapy back-
bone and BSI-201 in advanced uterine carcinosarcomas
was recently completed (NCT00687687). BSI-201, by ac-
tivating gamma-H2AX, induces cell cycle arrest in the
G2/M phase in tumor cell lines, and potentiates the cell
cycle effects of DNA damaging modalities in tumor cell
lines. Other ongoing studies include a feasibility trial of
CT and galunisertib (inhibitor of the kinase domain of
Type 1 TGF-B receptor) in patients with newly diag-
nosed or recurrent carcinosarcoma of the uterus or
ovary (NCT03206177) and the phase 1 study of seli-
nexor in combination with CT in patients with advanced
ovarian or endometrial cancers (NCT02269293).
Advanced-disease treatments
Recent chemotherapy trials in the advanced/recurrent
disease setting have not shown significant outcome im-
provements over prior single-agent chemotherapy
studies. For example, a phase 3 randomized trial of second-
line ixabepilone, an anti-tubulin epothilone, versus pacli-
taxel or doxorubicin in women with advanced EC failed to
meet its primary objective of improving OS in the ixabepi-
lone arm compared with the control chemotherapy arm. At
interim analysis, the study of futility for OS favored the
control chemotherapy arm (HR= 1.3; 95% CI: 1.0–1.7;
stratified log-rank test P = 0.0397), and the study was dis-
continued based on the interim OS results [68].
Hormonal strategies and antibody drug conjugates
Given the endocrine sex hormone relationship with
most ECs, agents that target these receptors and path-
ways have been evaluated and are in clinical use for EC
of low-grade endometrioid histology; however, they are
associated with limited efficacy. Megestrol acetate, a
progestin, was approved more than 40 years ago for the
palliative treatment of recurrent, metastatic breast and
endometrial cancers. More recently, the GOG-153 study
evaluated the combined hormonal strategy of alternating
tamoxifen and megestrol acetate based on the hypothesis
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that tamoxifen increases the expression of progesterone
receptors and thereby increases the efficacy of megestrol
acetate. Megestrol acetate at 80 mg twice daily every
3 weeks, alternating with tamoxifen 20 mg twice daily
every 3 weeks, was associated with an overall response
rate of 27% [69]. Responses were attenuated by grade,
which is correlated with hormone receptor status, with
rates of 38%, 24%, and 22% for grade 1, 2, and 3 disease,
respectively. Estrogen reduction by aromatase inhibitors,
specifically anastrozole and letrozole, has shown little
activity in EC in two prior studies [64, 65].
Elevated cyclin-dependant kinase 4 (CDK4) expression
is observed in 34% to 77% of endometrioid endometrial
cancers (EECs) and is considered to be an early event of
neoplastic transformation in EEC [70]. CDK4/6 mediate
the transition from G1 to S phase by associating with
D-type cyclins and regulating the phosphorylation state
of retinoblastoma. CDK4/6SA is significantly higher (P
= 0.002) in pathologically low-risk patients (not receiving
adjuvant chemotherapy, n = 74) than in intermediate- or
high-risk patients (receiving adjuvant chemotherapy, n =
35). Patients with high CDK4/6SA (>3.0) have signifi-
cantly (P = 0.024) shorter PFS than those with low
CDK4/6SA (<3.0) [71]. CDK4/6 inhibitors restore cell-
cycle control and halt tumor growth. In an effort to
improve the efficacy of treatment in this setting, a ran-
domized phase 2 trial of palbociclib (CDK4/6 inhibitor)
in combination with letrozole versus placebo in combin-
ation with letrozole for patients with estrogen receptor
(ER)-positive advanced or recurrent EC (NCT02730429)
and a phase 2 trial of ribociclib (cyclin D1 and CDK4/6
inhibitor) and letrozole in ER-positive advanced ovarian,
fallopian tube, primary peritoneal carcinomas and EC
(NCT02657928) are currently recruiting patients.
Luteinizing hormone-releasing hormone receptors
(LHRH-Rs) mediate antiproliferative activity in endo-
metrial cell lines, and approximately 80% of ECs express
LHRH-Rs, offering a potentially useful target in these tu-
mors [66, 67]. Zoptarelin doxorubicin is an [D-
Lys6]LHRH linked to doxorubicin, with activity in
LHRH-R-positive cancer cell lines [72, 73]. Zoptarelin
doxorubicin is internalized via LHRH-R and induces
apoptosis without activating the MDR-1 efflux pump
system, and it is less toxic than doxorubicin [73–76]. In
an initial study of 17 women with ovarian, endometrial,
or breast cancer who received various doses of zoptarelin
doxorubicin, 3 patients who received 160 mg/m2 and 3
patients who received 267 mg/m2 (maximally tolerated
dose) responded [77]. In a phase 2 study of 43 patients
with LHRH-R-positive advanced EC, 2 patients achieved
complete remission and 8 achieved partial remission fol-
lowing zoptarelin doxorubicin administration [78]. The
overall objective response and stable disease rates were
23% and 47%, respectively. The ZoptEC phase 3 trial
compared the efficacy and safety of zoptarelin doxorubicin
to doxorubicin alone. Patients were centrally randomized
in a 1:1 ratio and received either zoptarelin doxorubicin
(267 mg/m2) or doxorubicin (60 mg/m2) intravenously
every 3 weeks for up to 9 cycles. The median OS period
for patients treated with zoptarelin doxorubicin was
10.9 months compared with 10.8 months for patients
treated with doxorubicin. This was not a statistically
significant, clinically meaningful increase in OS, and thus
the ZoptEC phase 3 clinical study did not meet its primary
endpoint (unpublished data).
Folate receptor alpha (FRα) expression is associated with
high-grade, advanced-stage EC and a poor prognosis, par-
ticularly in serous-type tumors, [79, 80], thus providing an
attractive candidate for novel, targeted therapeutic strat-
egies in advanced EC. Mirvetuximab soravtansine is an
antibody-drug conjugate (ADC) comprised of an FRα-
binding antibody, cleavable linker, and the maytansinoid
DM4, a potent tubulin-targeting agent. A phase 1 expan-
sion study of mirvetuximab soravtansine in patients with
EC is currently ongoing (NCT02606305).
Other targeted therapies
Antiangiogenic therapies
Vascular endothelial growth factor (VEGF) is expressed
in most ECs and is associated with higher histologic
grade, lymphovascular space invasion, lymph node me-
tastasis, and deep myometrial invasion [81–86]. In the
GOG-229E study, bevacizumab therapy led to an overall
response rate of 14% in 52 women with persistent or re-
current EC treated with one or two prior cytotoxic regi-
mens [87]. Multiple phase 2 trials have demonstrated
improved PFS with bevacizumab monotherapy or in
combination with an mTOR inhibitor [88, 89]. The on-
going GOG-86P trial of bevacizumab with cytotoxic
agents has demonstrated a potential survival benefit
[90], and final results are anticipated in the near future.
Other anti-angiogenic agents have been investigated
but have shown limited activity; these agents include
thalidomide, aflibercept, sorafenib, and the small-
molecule tyrosine kinase inhibitors (TKIs) dovitinib,
nintedanib, brivanib, and sunitinib [91–94]. The GOG-
229F trial of aflibercept (VEGF ligand binding fusion) in
44 patients with advanced EC met its study endpoint of
PFS at 6 months but was associated with significant tox-
icities at the studied dose and schedule [95]. Cediranib, a
multi-target TKI, targets VEGF 1–3 and platelet-derived
growth factor β (PDGFβ) receptors, as well as c-Kit. The
recent GOG-229 J study of cediranib in advanced EC
demonstrated its sufficient activity and tolerability as
monotherapy treatment (Table 1) [87, 92, 95–101].
Lenvatinib, an oral receptor TKI, targets VEGF recep-
tors 1–3, fibroblast growth factor receptos1–4, RET,
KIT, and PDGFβ. Confirmed complete responses and
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partial responses were observed in 19 patients (14%)
and 29 patients (22%) treated with lenvatinib by
independent review and investigator assessment,
respectively [97]. The median PFS was 5.4 months,
and the median OS was 10.6 months. Lenvatinib is
being developed further in combination with
immunotherapy.
EGFR pathway inhibitors
In EC, epidermal growth factor receptor (EGFR) overex-
pression is common, and is associated with deep
myometrial invasion, tumor grade, and a poor prognosis
[102–104]. Low response rates have been reported for
the oral EGFR inhibitors gefitinib and erlotinib in phase
2 trials [105, 106].
HER2/neu is a member of the human epidermal
growth factor receptor (HER/EGFR/ERBB) family.
HER2/neu overexpression leads to alterations in cell
proliferation, migration, differentiation, and survival, as
well as the upregulation of the Ras/Raf/MAPK and
PI3K/AKT/mTOR pathways [107]. HER2/neu overex-
pression is seen in advanced type 2 cancers and is asso-
ciated with a poor prognosis [108, 109]. ERBB2/HER2 is
an RTK that mediates signaling via the PI3K and
mitogen-activated protein kinase (MAPK) pathways. Im-
portantly, ERBB2 was focally amplified with protein
overexpression in 25% of the serous or serous-like
tumors based on TCGA data [25]. A phase 2 trial of the
HER2/EGFR inhibitor lapatinib in molecularly unselected
advanced EC revealed limited activity, with an ORR of
3.3% and median PFS of 1.8 months [110]. A randomized
phase 2 trial (NCT01367002) evaluating CT in combin-
ation with trastuzumab, which as a single agent showed
limited activity in a previous phase 2 trial (ORR, 0%;
median PFS, 1.8 months) [111], closed due to poor ac-
crual. Ongoing trials of ado-trastuzumab emtansine and
afatinib (irreversible EGFR, HER2, and HER4 inhibitor)
for patients with EC and HER2-amplified or mutant can-
cers are accruing (NCT02675829, NCT02491099).
Inhibitors of the PI3K/Akt/mTOR pathway
Since the initial studies of nearly 20 years ago, a myriad
of approaches to target this pathway have been explored.
The initial studies of rapamycin analogs (rapalogs) that
bind directly to and allosterically inhibit mTOR1
revealed modest but reproducible antitumor activity
across the serous, endometrioid and clear cell histologic
subtypes, with some patients experiencing prolonged
stable disease. Several phase 2 trials have investigated
the use of mTOR inhibitors as single agents in advanced
EC. The objective response rates (ORRs) in those studies
ranged form 0% to 24%, and responses were higher in
chemotherapy-naïve patients (Table 2) [112–117].
The modest activity shown in these studies could be
secondary to the existence of intra- or inter-pathway
feedback loops (e.g., MAPK pathway) and from the in-
complete blockage of the pathway provided by the rapa-
logs. Correlative analyses of archival biospecimens have
failed to identify a predictive biomarker in EC, and these
initial studies also did not enrich for patients with ab-
normalities in the PI3K/Akt/mTOR pathway. These
studies may have been strengthened by limiting eligibil-
ity to patients with alterations in this pathway, although
it is also possible that a single or multiple target
biomarkers may be insufficient to predict for response
due to the inherent complexity of this pathway.
Rapalogs have also been evaluated in combination tri-
als. A phase 2 study of everolimus plus letrozole
reported a response rate of 32% and a clinical benefit
rate (CBR) of 40% [118]. Interim results of an ongoing
phase 2 trial of everolimus, letrozole and metformin
showed a partial response rate of 29%, and 38% of pa-
tients achieved stable disease [119]. The GOG-248 study
of temsirolimus with or without megestrol acetate in 71
patients revealed that adding the combination of megestrol
Table 1 Anti-angiogenic Therapies
Study Drug Target Prior Lines of Therapy Patients ORR mTTP/PFS (months) mOS (months)
Dalantercept [98] BMP9/10 1–2 28 0% 2.1 14.5
Trebananib [99] Tie2 Receptor 1–2 32 3.1% 2 6.6
Cediranib [96] VEGF/c-kit 1–2 48 12.5% 3.7 12.5
Sunitinib [91] VEGF/KIT/PDGFR ≤ 1 33 18.2% 3.0 19.4
Nintedanib [92] VEGF/FGFR/PDGFR 1–2 32 9.4% 3.1 10.1
Lenvatinib [97] VEGFR/FGFR/RET/KIT/PDGFRβ 1–2 133 14.3% 5.6 10.6
Aflibercept [95] VEGFR 1–2 44 7% 2.9 14.6
Bevacizumab [87] VEGFR 1–2 52 13.5% 4.2 10.6
Sorafenib [100] VEGF/Raf/Ras ≤ 1 39 5% 3.2 11.4
Thalidomide [101] VEGFR/bFGF 1–2 21 12.5% 1.7 6.3
ORR objective response rate, mTTP median time to progression, PFS progression-free survival, mOS median overall survival
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acetate and tamoxifen to temsirolimus did not enhance
activity. The study was closed early due to an excess of
venous thrombosis in the combination arm [120].
Due to the incomplete inhibition of mTORC1 targets
by rapalogs, and the feedback loops that exist, activation
of upstream PI3K signals [54, 55] can result. It has been
hypothesized that newer PI3K pathway agents, which
target further upstream in the pathway, will be more
clinically effective. Numerous phase 1b/2 clinical trials
evaluating catalytic mTOR, AKT, pan-PI3K, and dual
PI3K/mTOR inhibitors are underway.
mTOR inhibitors have also been combined with
chemotherapy. Two phase 1 trials in solid tumors using
CT with either ridaforolimus [121] or temsirolimus
[122] showed response rates of 25% and 82%, respect-
ively, in EC populations. However, a randomized phase 2
trial (GOG-86P) comparing CT with either temsirolimus
or bevacizumab or carboplatin plus ixabepilone and
bevacizumab to CT showed improved OS when bevaci-
zumab, but not temsirolimus, was added to CT [90].
Non-rapalog PI3K/AKT/mTOR inhibitors
There are multiple completed or ongoing single-agent
phase 2 clinical trials examining non-rapalog PI3K/
mTOR agents in EC. A phase 2, two-stage, two-arm
PIK3CA mutation stratified trial of MK-2206, an allo-
steric inhibitor of AKT, of previously treated endometrial
cancer also revealed limited single-agent activity in both
mutant (1 partial response) and wild-type (1 partial re-
sponse) EC populations, although activity was detected
in serous histology tumors with exploratory analysis, re-
vealing that all patients with a 6-month PFS had serous
EC. This study may have suffered from small patient
numbers in the mutant group, as well as poor drug
tolerance [123]. A phase 2 trial of the pan class I PI3K
inhibitor pilaralisib demonstrated minimal activity, with
an ORR of 6%, as did the phase 2 MAGGIE study of
GDC-0980, a dual PI3K/mTOR inhibitor, which also
demonstrated an ORR of 6% and limited antitumor ac-
tivity [124, 125]. Both studies were limited in that they
did not require an alteration in the PI3K/Akt/mTOR
axis. Similarly, a phase 2 double-strata (low grade vs
high grade) trial of BKM120, a pure PI3K inhibitor, in
previously treated EC demonstrated an ORR of 0%, and
was discontinued early due to excessive toxicity [126]. A
phase 2 trial of LY3023414, a PI3K/mTOR inhibitor
(NCT02549989), in EC with PI3K pathway activation
without concurrent resistance mutations is ongoing.
HER2/neu gene amplification and PIK3CA driver muta-
tions are common in uterine serous carcinoma. Preclin-
ical studies have shown that HER2-amplified serous cell
lines were more sensitive to growth inhibition by PI3K
inhibitors than HER2 non-amplified serous EC cell lines,
a potential future direction [127]. Of additional interest
is the combination with poly (ADP-ribose) polymerase
(PARP) inhibitors, as drugs targeting the PIK3/AKT/
mTOR pathway may interfere with DNA repair mecha-
nisms, as described below.
Metformin
Metformin is an oral biguanide agent that is known to
inhibit cellular proliferation and induce apoptosis, po-
tentially through inhibition of Mitochondrial complex 1
and AMPK activation and mTOR inhibition [128–131].
An association between metformin use and improved
outcomes in patients on prior single-agent mTOR inhib-
itors, as well as in the everolimus and letrozole combin-
ation, has been shown [118, 132]. Currently, there are
numerous metformin chemoprevention studies, as well
as studies of metformin combinations with standard
chemotherapy (NCT02065687) and with hormonal and
mTOR agents (NCT01797523).
PARP inhibitors
Preclinical studies have shown that inhibition of the PI3K/
akt/mTOR pathway may sensitize EC cell lines to PARP
inhibitors, and that loss of PTEN function may predict
sensitivity to PARP due to a synthetic lethality process.
This appears to be particularly true in a low-estrogenic
setting [123, 133]. A phase 2 study of the PARP inhibitor
niraparib in recurrent EC (NCT03016338) is active but
not yet recruiting.
Table 2 Single-Agent mTOR Inhibitor Studies in Endometrial Cancer







Temsirolimus [112] 29 None No 24% SD≥ 8 weeks: 69%
25 1–2 No 4% SD≥ 8 weeks: 46%
Everolimus [113] 28 1–2 No 0% SD: 43%
Everolimus [114] 44 1–2 No 9% SD: 27%
Ridaforolimus IV [115] 45 1–2 No 11% CBR: 29%
Ridaforolimus PO [116] 30 Adjuvant only No 9% SD: 52.9%
Ridaforolimus PO [117] 64 1–2 No 0% SD: 35%
IV intravenous, PO oral, SD stable disease, CBR clinical benefit rate
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In addition, a phase I study is exploring the role of the
PARP inhibitor olaparib in combination with the
mTORC1/2 inhibitor AZD2014 or the AKT inhibitor
AZD5363 for gynecological cancers, including advanced
ECs (NCT02208375).
Immunotherapy
Immune checkpoint inhibitors in the treatment of EC,
although potentially promising, have had until recently
limited reportable data. Programmed cell death-1 (PD-1)
and its ligand PD-L1 are expressed on the tumor-
infiltrating immune cells of 61% to 80% of primary ECs
[134, 135] and in 100% of metastatic ECs [134, 135].
Presence of tumor-infiltrating lymphocytes is also an in-
dependent prognostic factor in type I and II ECs [136].
The high mutation load in the POLE-mutated and MSI-
H EC subgroups is correlated with PD-1 expression
[133]. Approximately 26% of recurrent ECs harbor mis-
match repair deficiency (MMD-D) or POLE-E exomu-
clease domain mutations (POLE EDM) in the recurrent
disease setting, and may be excellent candidates for PD-
1 targeting immunotherapies [137]. The vast majority of
recurrent ECs are the copy-number low endometrioid
and copy-number high serous-like ECs, which may
warrant more tailored immunotherapy and combination
treatment approaches.
A phase 2 study evaluating the clinical activity of the
PD-1 inhibitor pembrolizumab in patients with colorec-
tal cancer demonstrated an immune-related PFS rates of
78% in patients with MMR-deficient cancer and 11% in
patients with MMR-proficient cancer, demonstrating
that MMR status predicts the clinical benefit of pembro-
lizumab [138]. In preliminary results from the phase 1b
KEYNOTE-028 study, there was a partial response of
13% among 24 pretreated patients with advanced EC
and PD-L1 expression ≥1% [139].
Pembrolizumab recently was granted FDA accelerated
approval for tissue or site agnostic use in the treatment of
patients with unresectable or metastatic solid tumors, in-
cluding EC, associated with MSI-H or MMR-deficient dis-
ease. This was the FDA’s first tissue or site agnostic
approval, which was based on data from five single-arm,
multi-cohort, multi-center, clinical trials of 149 patients
with MSI-H or MMR-deficient disease. The overall ORR
based on independent review was 39.6%, with 11 complete
responses and 48 partial responses. Responses lasted
6 months or longer in 78% of patients who responded.
Observations in several mouse models have shown that
the oral TKI lenvatinib appears to significantly decrease
the tumor-associated macrophage population, leading to
increased antitumor activity and upregulation of PD-1 sig-
nal inhibitors [140, 141]. A phase 1b/2 trial of lenvatinib
plus pembrolizumab in patients with selected solid tu-
mors, including EC, is ongoing (NCT02501096). Interim
results in 23 patients with advanced EC revealed an ORR
of 52% by independent review. Importantly, responses
were seen in both MSI-high and MSS patients [142].
Multiple monotherapy trials (NCT02628067, NCT
02912572, NCT02899793, NCT02630823), combination
immunotherapy trials (NCT03015129 NCT02982486),
and immunotherapy trials in combination with paclitaxel
and carboplatin (NCT02549209) are planned or ongoing.
Conclusions
Based on the increasing incidence and mortality associ-
ated with EC, and with only one recently approved ther-
apy for a subset of patients with advanced EC, the NCI
has published priorities for research on treating EC, with
a goal to integrate molecular and/or histologic stratifica-
tion into EC management. A recent international survey
reported that 94% of participants supported the concept
of treating patients in appropriate clinical trials. Since
2011, there has been a severe enrollment decline of 80%
for gynecologic oncology clinical trials due to decreased
federal funding and the consolidation of cooperative
groups within the NCI. A focus on designing clinical tri-
als to study new rationally combined therapeutic agents,
including molecularly targeted agents and immunother-
apy, in patients with EC is essential to the advancement
of cancer care and the improvement of outcomes among
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